| Overview |
| bs-7523R-Cy5.5 |
| phospho-Caveolin-2 (Tyr19) Polyclonal Antibody, Cy5.5 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Mouse, Rat |
| Specifications |
| Cy5.5 |
| Rabbit |
| KLH conjugated syntheticphosphopeptide derived from mouse Caveolin2 around the phosphorylation site of Tyr19. |
| Tyr19 |
| Polyclonal |
| #REF! |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 858 |
| Cytoplasm, Nucleus, Cell membrane |
| Caveolin 2 phospho Y19; p-Caveolin 2phospho Y19; CAV; CAV2; CAV2_HUMAN; Caveolae protein 20 kD; Caveolin 2; Caveolin 2 isoform a and b; Caveolin 2 isoform c; Caveolin-2; MGC12294; CAV2_HUMAN. |
| Cellular localization: Nucleus. Cytoplasm. Golgi apparatus membrane. Cell membrane. Membrane > caveola. Potential hairpin-like structure in the membrane. Membrane protein of caveolae. Tyr-19-phosphorylated form is enriched at sites of cell-cell contact and is translocated to the nucleus in complex with MAPK1 in response to insulin (By similarity). Tyr-27-phosphorylated form is located both in the cytoplasm and plasma membrane. CAV1-mediated Ser-23-phosphorylated form locates to the plasma membrane. Ser-36-phosphorylated form resides in intracellular compartments. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz